middle.news
How Will Vita Life Sciences Capitalize on 30% Growth in Malaysia and Singapore?
9:36am on Friday 12th of December, 2025 AEDT
•
Healthcare
Read Story
How Will Vita Life Sciences Capitalize on 30% Growth in Malaysia and Singapore?
9:36am on Friday 12th of December, 2025 AEDT
Key Points
FY2025 sales guidance of $91m-$92m, up from $79.5m in FY2024
Pre-tax profit expected between $13.2m and $13.7m, exceeding prior year
Malaysia and Singapore markets to deliver approximately 30% revenue growth
Australian market remains steady with expanding channel coverage
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Vita Life Sciences (ASX:VLS)
OPEN ARTICLE